Compare Citius Pharmaceuticals Inc (CTXR) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.49 (market cap $13.62M), while Vanguard Ultra Short Bond ETF trades at $49.49 (market cap $10.20B). The key difference: Vanguard Ultra Short Bond ETF is far larger — about 748.9× Citius Pharmaceuticals Inc's market cap, and Vanguard Ultra Short Bond ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 16 Days and Vanguard Ultra Short Bond ETF for 61 Days on average.
| CTXR | VUSB | |
|---|---|---|
Market Cap | $13.62M | $10.20B |
Volume | 132,438 | 2,664,667 |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.82 | $50.03 |
52-Week Low | $0.48 | $49.41 |
Typical Hold Time | 16 Days | 61 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.5082, up 5.72% today, amid a bearish technical trend but with oversold oscillators suggesting potential for a near-term bounce. The company reported its first revenue of $7 million in 2026 from LYMPHIR sales, yet remains deeply unprofitable with a net income margin of -651.27%. Analyst consensus is strongly positive with five buy ratings and a $5.00 price target, highlighting optimism around its oncology drug launch despite significant cash burn from operations.
The outlook hinges on successful commercialization of LYMPHIR to offset steep losses. Investment opportunity lies in the drug's market adoption and analyst bullishness, but risks include sustained negative cash flow, execution challenges, and the stock's high volatility. Shareholder value depends on translating revenue growth into profitability.
VUSB trades at $49.48, up 0.08% with minimal daily movement. Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The stock faces resistance at $50 and support at $49. Recent news highlights potential benefits from short-term bond strategies amid Federal Reserve rate uncertainty.
The outlook remains cautious due to bearish technical signals and interest rate sensitivity. Opportunities include dividend stability with recent payouts, but risks involve Fed policy shifts and market volatility. Investors should weigh short-term bond appeal against broader economic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
